MedTrace Logo

High Dose D-Serine as Adjuvant Treatment for Recent Onset Schizophrenia

NCT01459029 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2011-10-25

No results posted yet for this study

Summary

The purpose of this study is to compare efficacy and safety of add-on treatment with a moderately high dose of D-serine, an NMDA-glycine site agonist, in young, recent onset schizophrenia patients who suffer from significant symptoms despite treatment with antipsychotics.

Conditions

Interventions

DRUG

D-serine

Adjuvant treatment with D-serine up to 6000 mg/day vs. placebo

Sponsors & Collaborators

  • Herzog Hospital

    collaborator OTHER

  • Hadassah Medical Organization

    lead OTHER

Principal Investigators

  • Amit Lotan, MD · Hadassah Medical Organization

  • Bernard Lerer, MD · Hadassah Medical Organization

  • Uriel Heresco-Levy, MD · Ezrath Nashim - Herzog Memorial Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2013-10-31
Completion
2014-10-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01459029 on ClinicalTrials.gov